Pfizer will invest $750 million to upgrade its facility in Kalamazoo, Michigan. According to a release, the focus will be on injectable medicines, with Pfizer angling to position its on-site modular aseptic processing (MAP) facility as “one of the most technologically advanced sterile injectable facilities in the world.”

The project is expected to create around 300 new jobs. Specifically, in this second phase of Pfizer’s MAP project, the company will fold in advanced aseptic manufacturing equipment, systems and design, which will include self-contained modular manufacturing lines. The company is eyeing production of products at MAP 2 that rely on mRNA and “ultra-low temperature storage.”

Pfizer also uses its Kalamazoo plant to make its oral COVID antiviral Paxlovid. As part of a production push for the med, Pfizer will create hundreds of highly-skilled jobs at the site, which is among the company’s largest for production. In June, the company formally unveiled a $120 million investment at the Kalamazoo campus alongside plans to create 250 new jobs, with the aim to bolster production of Paxlovid, also known as nirmatrelvir and ritonavir tablets.

At Kalamazoo, Pfizer says it also makes liquid and semi-solid medicines plus active pharmaceutical ingredients. The 400,000-sq ft MAP facility, for its part, employs 3,000 staffers and contractors, the company said in its release.